Comparative Pharmacology
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus REVONTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus REVONTO.
ORPHENADRINE CITRATE vs REVONTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties. Its exact mechanism of action is not fully understood, but it is believed to exert its effects by blocking muscarinic acetylcholine receptors and possibly by acting as an NMDA receptor antagonist. It may also have local anesthetic and antihistaminic properties.
Remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing the effects of GABA to produce sedation and anxiolysis.
100 mg orally twice daily. Maximum: 250 mg/day.
4 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 14 hours (range 11–20 hours) in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 18–20 hours in healthy adults, allowing once-daily dosing.
Primarily renal excretion of metabolites; less than 10% excreted unchanged. Also undergoes biliary excretion with fecal elimination of conjugates.
Renal excretion of unchanged drug accounts for <1% of the dose; fecal excretion via biliary elimination is the primary route (≈90%), with the remainder as metabolites.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant